Abstract:Objective To investigate the risk factors of non-reflow after ST-segment elevation myocardial infarction(STEMI)by percutaneous coronary intervention(PCI).Methods A total of 100 STEMI patients who underwent PCI treatment in Foshan Nanhai District People′s Hospital from January 2018 to April 2020 were selected as the research subjects.According to the blood flow of thrombolysis in myocardial infarction(TIMI)in patients with acute myocardial infarction,they were divided into non-reflow group(27 cases)and reflow group(73 cases).Relevant data were collected and the related risk factors of non-reflow after STEMI by PCI.Results The proportion of smoking history,calciumdependent C-type lectin-like receptor 2(CLEC-2)and low-density lipoprotein cholesterol(LDL-C)levels in the nonreflow group were 33.33%,(239.15±56.45)pg/mL,(3.53±1.21)mmol/L,respectively,higher than those in the reflow group of 12.33%,(185.07±33.96)pg/mL,and(2.32±0.87)mmol/L,and the differences were statistically significance(P<0.05).Diastolic blood pressure,systolic blood pressure,and high-density lipoprotein cholesterol(HDL-C)levels in the flow group were(65.78±16.21)mmHg,(101.67±24.96)mmHg,and(1.44±0.59)mol/L,respectively,lower than those in the reflow group of(72.82±13.48)mmHg,(115.21±23.67)mmHg,(2.01±0.48)mol/L,and the differences were statistically significance(P<0.05).Multivariate Logistic regression analysis showed that smoking history(β=1.269,OR=3.556,95%CI=1.230-10.280),CLEC-2 ≥214.58 pg/mL(β=1.749, OR=5.750,95%CI=1.254-26.358),LDL-C≥3.37 mmol/L(β=2.015, OR=7.500,95%CI=1.645-34.197),systolic blood pressure <120 mmHg(β=1.255, OR=3.509,95%CI=0.750-16.422)were independent risk factors of non-reflow after STEMI by PCI(P<0.05).Conclusion Non-reflow after STEMI by PCI is closely related to smoking history,CLEC-2,LDL-C,and systolic blood pressure,and clinical prevention and control needs to be strengthened.
刘俊强. ST段抬高型急性心肌梗死急诊冠脉介入术后无复流现象的相关危险因素分析[J]. 中国当代医药, 2021, 28(22): 69-71转75.
LIU Jun-qiang. Analysis of related risk factors of non-reflow after emergency coronary intervention for ST-segment elevation myocardial infarction. 中国当代医药, 2021, 28(22): 69-71转75.